Kimball Electronics Posts Better-Than-Expected Earnings, Joins Terawulf, Dlocal, Equinox Gold And Other Big Stocks Moving Higher On Thursday - Bullish ( NYSE:BLSH ) , DLocal ( NASDAQ:DLO )
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Thursday. Shares of Kimball Electronics Inc KE rose sharply during Thursday's session after the company reported better-than-expected quarterly financial results.
Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus
KOD's Q2 loss widens as it ramps up clinical studies for three key eye disease treatments with pivotal data readouts planned.
Kodiak Sciences Beats Q2 Loss Estimates
Kodiak Sciences ( NASDAQ:KOD ) , a biotechnology company specializing in retinal disease therapies, released its Q2 2025 earnings results on August 13, 2025. The most notable news: the company reported a GAAP net loss of $54.3 million, translating to a GAAP EPS loss of $ ( 1.03 ) , beating ...
Why Is Kodiak Sciences ( KOD ) Up 10.5% Since Last Earnings Report?
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus
KOD reports a wider-than-expected loss for the first quarter of 2025. The company provides updates regarding its pipeline development plans.
Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences ( KOD )
Kodiak Sciences (KOD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus
KOD reports a narrower-than-expected loss for the fourth quarter of 2024. The company provides updates regarding its pipeline development plans.
KOD Completes Enrollment in Phase III Study for Eye Disease Candidate
Kodiak reports completing patient enrollment in its late-stage study evaluating tarcocimab for diabetic retinopathy.
Polaris, General Motors And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Greenfire Resources ( NYSE:GFR ) , General Motors ( NYSE:GM )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 100 points on Tuesday. Shares of Polaris Inc. PII fell sharply in today's pre-market trading following fourth-quarter results.
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates
Kodiak stock skyrockets 271% in six months on the back of positive updates from the tarcocimab program for treating retinal vascular diseases.
Crude Oil Surges 2%; Tesla Shares Plummet - Jayud Global Logistics ( NASDAQ:JYD ) , Carmell ( NASDAQ:CTCX )
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling over 300 points on Thursday. The Dow traded down 0.79% to 42,208.88 while the NASDAQ fell 0.89% to 19,138.50. The S&P 500 also fell, dropping, 0.79% to 5,834.99. In trading on Thursday, real estate shares fell ...
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025.
Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket - American Battery Tech ( NASDAQ:ABAT )
Shares of Rumble Inc. RUM rose sharply in today's pre-market trading after the company announced it has entered into a definitive agreement for a strategic investment of $775 million from Tether.
KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential
Kodiak stock surges as Jefferies upgrades it to a "BUY" rating based on the significant potential of its pipeline candidates for retinal disease indications.
Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic Diseases - Kodiak Sciences ( NASDAQ:KOD )
CAMBRIDGE, Mass., Dec. 9, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" ( I to ITM ) , ranging from target validation and antibody discovery through preclinical research, today announced a collaboration with Kodiak Sciences ...
Pactiv Evergreen, RealReal, Kodiak Sciences And Other Big Stocks Moving Higher On Monday - Akso Health ( NASDAQ:AHG ) , Alibaba Gr Hldgs ( NYSE:BABA )
U.S. stocks were lower, with the Nasdaq Composite falling around 100 points on Monday. Shares of Pactiv Evergreen Inc. PTVE rose sharply during Monday's session after the company announced it will merge with Novolex in which Pactiv shareholders will receive $18.00 per share in cash.
Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock - Kodiak Sciences ( NASDAQ:KOD )
Jefferies has upgraded Kodiak Sciences Inc. KOD, a biopharmaceutical company focused on retinal ( eye ) diseases. Kodiak's lead investigational medicine, tarcocimab, is an anti-VEGF antibody biopolymer conjugate under development for high-prevalence retinal vascular diseases.
Kodiak Sciences Inc. ( KOD ) Just Flashed Golden Cross Signal: Do You Buy?
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus
KOD reports a narrower-than-expected loss for the third quarter of 2024. The company provides updates regarding its pipeline development plans.
Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks
KOD is evaluating tarcocimab in a phase III diabetic retinopathy study, which is set to form the basis for a regulatory filing across three eye disease indications.
Why Is Kodiak Sciences ( KOD ) Down 8.1% Since Last Earnings Report?
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kodiak ( KOD ) Q2 Loss Narrower Than Expected, Pipeline in Focus
Kodiak (KOD) reports a narrower-than-expected loss for the second quarter of 2024. The company provides updates regarding its pipeline development plans.
All You Need to Know About Kodiak Sciences ( KOD ) Rating Upgrade to Buy
Kodiak Sciences (KOD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ophthalmologists Favor Genentech's Vabysmo and Regeneron's Eylea HD for Diabetic Macular Edema Treatment Despite Payer Constraints
EXTON, PA., June 20, 2024, June 24, 2024 ( GLOBE NEWSWIRE ) -- The treatment landscape for Diabetic Macular Edema ( DME ) continues to evolve, with innovative therapies and emerging data significantly shaping prescribing patterns.
Should You Hold Kodiak Sciences ( KOD ) Stock in Your Portfolio?
Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.
Why Is Kodiak Sciences Down 26.2% Since Last Earnings Report?
It has been about a month since the last earnings report for Kodiak Sciences Inc. ( NASDAQ:KOD ) . Shares have lost about 26.2% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Kodiak Sciences due for a ...
Why Is Kodiak Sciences Down 26.2% Since Last Earnings Report? - Kodiak Sciences ( NASDAQ:KOD ) , Halozyme Therapeutics ( NASDAQ:HALO )
It has been about a month since the last earnings report for Kodiak Sciences Inc. KOD. Shares have lost about 26.2% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Kodiak Sciences due for a breakout?
Why Is Kodiak Sciences ( KOD ) Down 26.2% Since Last Earnings Report?
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kodiak ( KOD ) Q1 Loss Narrower Than Expected, Pipeline in Focus
Kodiak (KOD) reports better-than-expected first-quarter 2024 results and provides updates regarding its pipeline development plans.
Kodiak ( KOD ) Counts on Tarcocimab Program Despite Setbacks
Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.
Kodiak ( KOD ) Stock Falls on Q4 Earnings Miss, Pipeline in Focus
Kodiak (KOD) reports a wider-than-expected loss for fourth-quarter 2023. The company provides updates regarding its pipeline development plans.
Take the Zacks Approach to Beat the Market: NVIDIA, Dell, Modine in Focus
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
US Stocks Flat; Initial Jobless Claims Fall To 210,000
US Stocks Flat. Initial Jobless Claims Fall To ...
US Stocks Flat; Initial Jobless Claims Fall To 210,000 - Avalo Therapeutics ( NASDAQ:AVTX ) , Biodexa Pharmaceuticals ( NASDAQ:BDRX )
U.S. stocks traded mixed this morning, with the Dow Jones index trading almost flat on Thursday. Following the market opening Thursday, the Dow traded down 0.02% to 39,753.17 while the NASDAQ fell 0.08% to 16,385.80. The S&P 500 also rose, gaining, 0.04% to 5,250.38.
Merck ( MRK ) Unit to Buy Elanco's Aqua Business for $1.3B
Merck's (MRK) Animal Health unit is set to strengthen its position with the acquisition of Elanco Animal Health's aqua business for $1.3 billion. The transaction is expected to close by mid-2024.
Vertex's ( VRTX ) Q4 Earnings and Sales Surpass Estimates
Vertex's (VRTX) fourth-quarter earnings and revenues surpass estimates. The company reports encouraging data on triple combination of vanzacaftor studies.
TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up
TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.
Biogen ( BIIB ) to Stop Selling Alzheimer's Disease Drug Aduhelm
Biogen (BIIB) aims to build a leading Alzheimer's disease franchise with the new drug Leqembi. The company quits commercializing the controversial Alzheimer's disease drug, Aduhelm.
Dr. Reddy's ( RDY ) Q3 Earnings and Revenues Surpass Estimates
Dr. Reddy's (RDY) reports better-than-expected fiscal third-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in core businesses in North America and Europe.
Kodiak Sciences Inc. ( KOD ) Up 43.6% Since Last Earnings Report: Can It Continue?
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
EyePoint ( EYPT ) Surges 178% on Upbeat Phase II Eye Disease Data
EyePoint (EYPT) announces positive top-line data from the phase II study of its investigational candidate, EYP-1901, in the treatment of wet age-related macular degeneration. The stock rallies 178%.
Kodiak ( KOD ) Beats Q3 Earnings, Provides Pipeline Updates
Kodiak (KOD) reports better-than-expected third-quarter 2023 results and provides updates regarding its pipeline development plans.
Why StoneCo Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Collective Audience ( NASDAQ:CAUD ) , ReAlpha Tech Corp ( NASDAQ:AIRE )
StoneCo Ltd. STNE shares rose in pre-market trading after the company reported upbeat results for its third quarter on Friday. StoneCo posted adjusted earnings of 27 cents per share, beating market estimates of 22 cents per share. The company's sales came in at $643.35 million versus expectations ...
What's Going On With Kodiak Sciences ( KOD ) Stock Today? - Kodiak Sciences ( NASDAQ:KOD )
Kodiak Sciences Inc KOD said its Phase 3 GLOW superiority study evaluating tarcocimab tedromer 5 mg in moderately severe to severe NPDR met its one-year primary endpoint. Kodiak paused further development of tarcocimab after its GLEAM and GLIMMER studies in diabetic macular edema did not meet ...
Tesla stock gains while Ryanair shares surge on airline's dividend plan
Shares in POSCO, Ryanair, Lumen, Tesla, and Kodiak Sciences were all active in pre-market trading ...
's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Shopify ( NYSE:SHOP ) , Kodiak Sciences ( NASDAQ:KOD ) , Lemonade ( NYSE:LMND ) , Alpine Immune Sciences ( NASDAQ:ALPN )
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance to uncover new information.
Kodiak Sciences Inc. ( KOD ) Down 19.9% Since Last Earnings Report: Can It Rebound?
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why WestRock Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Alarum Technologies ( NASDAQ:ALAR ) , Amkor Tech ( NASDAQ:AMKR )
American Rebel Holdings, Inc. AREB rose 39.7% to $1.25 in pre-market trading. American Rebel announced Wednesday, that its safe subsidiary Champion Safe was bombarded with calls from safe dealers and customers looking for alternatives to safes made by Liberty Safe. Artelo Biosciences, Inc.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD
NEW YORK, Aug. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kodiak Sciences Inc. ( "Kodiak" or the "Company" ) ( NASDAQ: KOD ) . Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Kodiak ( KOD ) Q2 Earnings Miss, New Lead Candidate in Focus
Kodiak (KOD) reports weaker-than-expected results in second-quarter 2023. The company also provides an update on the status of its pipeline after discontinuing the tarcocimab program.
